| | Business Summary | | Praecis
Pharmaceuticals
Incorporated
is
a
drug
discovery
and
development
company
with
a
lead
product,
abarelix
depot,
for
the
treatment
of
prostate
cancer.
In
December
2000,
the
Company
submitted
to
the
Food
and
Drug
Administration
(FDA)
a
new
drug
application
for
abarelix
depot
for
the
treatment
of
prostate
cancer.
The
Company
is
also
developing
abarelix
depot
for
the
treatment
of
women
with
diseases
that
respond
to
a
reduction
of
the
female
hormone
estrogen,
such
as
endometriosis.
Praecis
is
developing
Apan,
its
drug
candidate
for
the
treatment
of
Alzheimer's
disease.
Apan
treats
what
the
Company
believes
to
be
the
underlying
cause
of
Alzheimer's
disease,
rather
than
the
symptoms.
Given
the
clinical
and
market
opportunity
in
treating
back
pain,
the
Company
licensed
Latranal,
a
proprietary
topical
composition
that
it
is
developing
for
the
relief
of
localized
muscle,
tendon
or
neuropathic
related
pain
and,
in
particular,
chronic
back
pain. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | Praecis
Pharmaceuticals
is
a
drug
discovery
and
development
company
whose
lead
product,
abarelix-depot,
is
in
clinical
trials
to
determine
its
effectiveness
in
treating
prostate
cancer.
For
the
six
months
ended
6/30/01,
revenues
fell
70%
to
$5.7
million.
Net
loss
totaled
$24.8
million,
up
from
$4.5
million.
Revenues
reflect
reduced
amounts
earned
under
the
Company's
corporate
collaboration
agreements.
Loss
also
reflects
increased
sales
and
marketing
expenses. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Malcolm Gefter, Ph.D., 59
Chairman,
Pres, CEO | $430K | $372K | Kevin McLaughlin, 44
CFO,
Sr. VP, Treasurer, Sec. | 234K | 982K | Marc Garnick, M.D., 54
Exec.
VP and CMO | 314K | 1.9M | Dean Falb, Ph.D., 40
Sr.
VP, Research | 205K | 1.6M | | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/p/prcs.gif)